机构：[a]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[b]Department of Radiation Oncology, Cyberknife Center and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China[c]Department of Oncology, Lianyungang First People’s Hospital, Lianyungang, China[d]Huaxi Student Society of Oncology Research, West China School of Medicine, Sichuan University, Chengdu, China四川大学华西医院[e]Department of Oncology, The Affiliated Hospital of Luzhou Medical College, Luzhou, China[f]Laboratory of Stem Cell Biology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[g]Center of Radiation Oncology, Sichuan Provincial Cancer Hospital. Chengdu, China四川省肿瘤医院
Purpose: This study aimed to examine the effect of the novel recombinant human endostatin (rh-Endo) protein on tumor vasculature, and to explore and evaluate the optimal scheduling of rh-Endo and radiotherapy (RT). Methods: Tumor-perfusion parameters and hypoxia were monitored after rh-Endo treatment in 10 nonsmall cell lung-cancer (NSCLC) patients. Eight-week female C57BL/6J mice were randomized to receive rh-Endo or control (saline) once daily for 12 days when Lewis lung carcinoma (LLC) reached approximately 100-150 mm(3). On planned days, tumors were measured for cell apoptosis, microvessel density, pericytes, blood-vessel morphology, and tumor hypoxia. The tumor response under different combinations of rh-Endo and RT schedules was evaluated. Results: Tumor hypoxia was significantly reduced 5 days after rh-Endo in NSCLC patients, and a similar result was found in the LLC mouse model. The anti-tumor effect was markedly enhanced when RT was administered within the remodeling period compared to any other treatment schedule. rh-Endo treatment remodeled the tumor vasculature after 5 days by reducing microvessel density and increasing pericytic coverage of the vessel endothelium. Conclusion: This study demonstrated decreased hypoxia in animals and patients upon rh-Endo treatment, which also enhanced the radioresponse within the vasculature-remodeling period. The optimal clinical combination of rh-Endo and RT warrants further investigation. (c) 2012 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 106 (2013) 130-137
基金：
National Major Project of China [2011ZX09302-001-01]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [30870734, 81172131, 81201754]; National Basic Research Program of ChinaNational Basic Research Program of China [2009CB941202]; 11th Five Years Special Foundation for State Major Science and Technology of China [2008ZX09312]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2013]版：
大类|2 区医学
小类|2 区肿瘤学2 区核医学
最新[2023]版：
大类|1 区医学
小类|2 区肿瘤学2 区核医学
JCR分区：
出版当年[2013]版：
Q1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ1ONCOLOGY
最新[2023]版：
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
第一作者机构：[a]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China[b]Department of Radiation Oncology, Cyberknife Center and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
共同第一作者：
通讯作者：
通讯机构：[a]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China[*1]Division of Thoracic Oncology and State Key Laboratory of Biotherapy, West China Hospital, West China School of Medicine, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Mao-Bin Meng,Xiao-Dong Jiang,Lei Deng,et al.Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence[J].RADIOTHERAPY AND ONCOLOGY.2013,106(1):130-137.doi:10.1016/j.radonc.2012.10.022.
APA：
Mao-Bin Meng,Xiao-Dong Jiang,Lei Deng,Fei-Fei Na,Jia-Zhuo He...&You Lu.(2013).Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence.RADIOTHERAPY AND ONCOLOGY,106,(1)
MLA：
Mao-Bin Meng,et al."Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: Experimental and clinical evidence".RADIOTHERAPY AND ONCOLOGY 106..1(2013):130-137
医学